Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Total Current Liabilities (2021 - 2025)

Historic Total Current Liabilities for Indivior Pharmaceuticals (INDV) over the last 5 years, with Q3 2025 value amounting to $965.0 million.

  • Indivior Pharmaceuticals' Total Current Liabilities changed N/A to $965.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $965.0 million, marking a year-over-year change of. This contributed to the annual value of $924.0 million for FY2024, which is 2786.89% down from last year.
  • According to the latest figures from Q3 2025, Indivior Pharmaceuticals' Total Current Liabilities is $965.0 million.
  • Indivior Pharmaceuticals' Total Current Liabilities' 5-year high stood at $1.3 billion during Q4 2023, with a 5-year trough of $804.0 million in Q4 2021.
  • In the last 5 years, Indivior Pharmaceuticals' Total Current Liabilities had a median value of $1.0 billion in 2025 and averaged $1.0 billion.
  • In the last 5 years, Indivior Pharmaceuticals' Total Current Liabilities skyrocketed by 2674.13% in 2022 and then crashed by 2786.89% in 2024.
  • Quarter analysis of 5 years shows Indivior Pharmaceuticals' Total Current Liabilities stood at $804.0 million in 2021, then rose by 26.74% to $1.0 billion in 2022, then rose by 25.71% to $1.3 billion in 2023, then fell by 27.87% to $924.0 million in 2024, then increased by 4.44% to $965.0 million in 2025.
  • Its Total Current Liabilities stands at $965.0 million for Q3 2025, versus $1.1 billion for Q2 2025 and $1.0 billion for Q1 2025.